Partner With Us NRI

Company details

6M Return -39.04%
1Y Return -53.10%
Mkt Cap.(Cr) 5,511.12
Volume 15,624
Div Yield 1.42%
OI Chg %
Volume 15,624

Open Free Demat Account Online with ICICIDIRECT


  • swot

  • technicals

  • deals

  • shareholding


Delivery and volume

Our Research View

Trading recommendation

Data not found

Investment recommendation

Call Date

30 May 2022

Entry Price


Target Price



12-18 Month


  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio


Operating Profit(Cr.)

Profit after Tax(Cr.)


Reserves and Surplus



Operating Profit

Profit after tax





Equity Capital: 4,741.49 Cr FV: 1.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 23,827.16 -46,760.12
LAST 3M 70,430.22 -89,034.55
LAST 6M 139,403.88 -217,329.33
LAST 12M 236,343.35 -248,677.18


  • About Company
  • Company Info
  • Listing Info
  • Jubilant Pharma Limited is engaged in the Pharmaceutical sector. The company has its market capitalization worth INR 11,533.55 crore as of 16th April 2021. The company was incorporated in 1978. The company has reported quarterly revenue of INR 828.94 crore at the end of December 2020. This company is listed on the Bombay Stock Exchange (BSE), having the code 530019 and on the National Stock Exchange (NSE) with the symbol JUBLPHARMA. The company is headquartered in Noida. It is a pharmaceutical company that offers products and services across the pharma value chain that includes manufacturing and supply of Allergy Therapy Products, Active Pharmaceutical Ingredients. Jubilant Pharmova Limited is a manufacturer and supplier of active pharmaceutical ingredients, radiopharmaceuticals, solid dosage formulations, advanced intermediates, allergy therapy products and nutritional products. It focuses on catering to unmet medical needs at a very affordable price. Pharmaceuticals, contract R&D providers, and patented new products are the company's three market divisions. Via a network of 49 radio pharmacies in the United States, the organisation produces and distributes radiopharmaceuticals. In Bengaluru and Noida, India, it has established two world-class research centres. Shyam S Bhartia, the company's director, oversees procedures. The company reported record profitability with annual revenue of INR 91544 million during the year, which is up by 0.5% year-on-year. In the same year, the company demerged its LSI (Life Science Ingredients) to create unique entities focused on Pharmaceuticals and LSI businesses. Jubilant Pharmova recorded a splurge of 52% year-on-year growth in quarter three. The CDMO and generics business of the company drove the increase in financials. In 2021, Fitch ratings upgraded Jubilant Pharmova Limited from BB- to BB. The up-gradation is a clear reflection of the improvements in the business profile. As of April 2021, the company announced the completion of safety and absorption studies in healthy human volunteers using a novel oral formulation of Remdesivir. The company entered into a non-exclusive licence agreement with Gilead Sciences Inc., which granted the rights to manufacture register and sell Gilead's Remdesivir in India and 126 other countries. The launch of this oral formulation of Covid medicine is likely to affect the company's growth positively.

Read More

Registered Address

Bhartiagram Gajraula, , Amroha, Uttar Pradesh, 244223

Tel : 91-5924-267200
Email : investors:jubl.com/support:jubl.com
Website : http://www.jubl.com


Alankit Assignments Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 530019
Book Closure Date (Month) :
BSE Group : A
ISIN : INE700A01033

ICICIdirect Jubilant Pharmova Ltd FAQ

You can buy Jubilant Pharmova Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Jubilant Pharmova Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Jun 28, 2022 04:01 PM the closing price of Jubilant Pharmova Ltd was ₹ 346.00.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Jun 28, 2022 04:01 PM, the market cap of Jubilant Pharmova Ltd stood at ₹ 5,511.12.
The latest PE ratio of Jubilant Pharmova Ltd as of Jun 28, 2022 04:01 PM is 13.53
The latest PB ratio of Jubilant Pharmova Ltd as of Jun 28, 2022 04:01 PM is 0.95
The 52-week high of Jubilant Pharmova Ltd is ₹ 766.85 while the 52-week low is ₹ 317.65 .
According to analyst recommendations, Jubilant Pharmova Ltd has a “Buy” rating for the long term.

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote